Accessibility Statement Skip Navigation
  • PRNewswire.com
  • Resources
  • +91 22-69790010
  • Client Login
  • Send a Release
PR Newswire: news distribution, targeting and monitoring
  • News
  • Products
  • Contact
When typing in this field, a list of search results will appear and be automatically updated as you type.

Searching for your content...

No results found. Please use Advanced Search to search all press releases.
  • News in Focus
      • Browse News Releases

      • All News Releases
      • All Public Company
      • Multimedia Gallery

      • All Multimedia
      • All Photos
      • All Videos
  • Business & Money
      • Auto & Transportation

      • Aerospace & Defense
      • Air Freight
      • Airlines & Aviation
      • Automotive
      • Maritime & Shipbuilding
      • Railroads & Intermodal Transportation
      • Supply Chain/Logistics
      • Transportation, Trucking & Railroad
      • Travel
      • Trucking & Road Transportation
      • View All Auto & Transportation

      • Business Technology

      • Blockchain
      • Broadcast Tech
      • Computer & Electronics
      • Computer Hardware
      • Computer Software
      • Data Analytics
      • Electronic Commerce
      • Electronic Components
      • Electronic Design Automation
      • Financial Technology
      • High Tech Security
      • Internet Technology
      • Nanotechnology
      • Networks
      • Peripherals
      • Semiconductors
      • View All Business Technology

      • Entertain­ment & Media

      • Advertising
      • Art
      • Books
      • Entertainment
      • Film & Motion Picture
      • Magazines
      • Music
      • Publishing & Information Services
      • Radio & Podcast
      • Television
      • View All Entertain­ment & Media

      • Financial Services & Investing

      • Accounting News & Issues
      • Acquisitions, Mergers & Takeovers
      • Banking & Financial Services
      • Bankruptcy
      • Bond & Stock Ratings
      • Conference Call Announcements
      • Contracts
      • Cryptocurrency
      • Dividends
      • Earnings
      • Earnings Forecasts & Projections
      • Financing Agreements
      • Insurance
      • Investments Opinions
      • Joint Ventures
      • Mutual Funds
      • Private Placement
      • Real Estate
      • Restructuring & Recapitalisation
      • Sales Reports
      • Shareholder Activism
      • Shareholder Meetings
      • Stock Offering
      • Stock Split
      • Venture Capital
      • View All Financial Services & Investing

      • General Business

      • Awards
      • Commercial Real Estate
      • Corporate Expansion
      • Earnings
      • Environmental, Social and Governance (ESG)
      • Human Resource & Workforce Management
      • Licensing
      • New Products & Services
      • Obituaries
      • Outsourcing Businesses
      • Overseas Real Estate (non-US)
      • Personnel Announcements
      • Real Estate Transactions
      • Residential Real Estate
      • Small Business Services
      • Socially Responsible Investing
      • Surveys, Polls & Research
      • Trade Show News
      • View All General Business

  • Science & Tech
      • Consumer Technology

      • Artificial Intelligence
      • Blockchain
      • Cloud Computing/Internet of Things
      • Computer Electronics
      • Computer Hardware
      • Computer Software
      • Consumer Electronics
      • Cryptocurrency
      • Data Analytics
      • Electronic Commerce
      • Electronic Gaming
      • Financial Technology
      • Mobile Entertainment
      • Multimedia & Internet
      • Peripherals
      • Social Media
      • STEM (Science, Tech, Engineering, Math)
      • Supply Chain/Logistics
      • Wireless Communications
      • View All Consumer Technology

      • Energy & Natural Resources

      • Alternative Energies
      • Chemical
      • Electrical Utilities
      • Gas
      • General Manufacturing
      • Mining
      • Mining & Metals
      • Oil & Energy
      • Oil & Gas Discoveries
      • Utilities
      • Water Utilities
      • View All Energy & Natural Resources

      • Environ­ment

      • Conservation & Recycling
      • Environmental Issues
      • Environmental Policy
      • Environmental Products & Services
      • Green Technology
      • Natural Disasters
      • View All Environ­ment

      • Heavy Industry & Manufacturing

      • Aerospace & Defence
      • Agriculture
      • Chemical
      • Construction & Building
      • General Manufacturing
      • HVAC (Heating, Ventilation & Air-Conditioning)
      • Machinery
      • Machine Tools, Metalworking & Metallurgy
      • Mining
      • Mining & Metals
      • Paper, Forest Products & Containers
      • Precious Metals
      • Textiles
      • Tobacco
      • View All Heavy Industry & Manufacturing

      • Telecomm­unications

      • Carriers & Services
      • Mobile Entertainment
      • Networks
      • Peripherals
      • Telecommunications Equipment
      • Telecommunications Industry
      • VoIP (Voice over Internet Protocol)
      • Wireless Communications
      • View All Telecomm­unications

  • Lifestyle & Health
      • Consumer Products & Retail

      • Animals & Pets
      • Beers, Wines & Spirits
      • Beverages
      • Bridal Services
      • Cannabis
      • Cosmetics & Personal Care
      • Fashion
      • Food & Beverages
      • Furniture & Furnishings
      • Home Improvement
      • Household, Consumer & Cosmetics
      • Household Products
      • Jewellery
      • Non-Alcoholic Beverages
      • Office Products
      • Organic Food
      • Product Recalls
      • Restaurants
      • Retail
      • Supermarkets
      • Toys
      • View All Consumer Products & Retail

      • Entertain­ment & Media

      • Advertising
      • Art
      • Books
      • Entertainment
      • Film & Motion Picture
      • Magazines
      • Music
      • Publishing & Information Services
      • Radio & Podcast
      • Television
      • View All Entertain­ment & Media

      • Health

      • Biometrics
      • Biotechnology
      • Clinical Trials & Medical Discoveries
      • Dentistry
      • FDA Approval
      • Fitness/Wellness
      • Health Care & Hospitals
      • Health Insurance
      • Infection Control
      • International Medical Approval
      • Medical Equipment
      • Medical Pharmaceuticals
      • Mental Health
      • Pharmaceuticals
      • Supplementary Medicine
      • View All Health

      • Sports

      • General Sports
      • Outdoors, Camping & Hiking
      • Sporting Events
      • Sports Equipment & Accessories
      • View All Sports

      • Travel

      • Amusement Parks & Tourist Attractions
      • Gambling & Casinos
      • Hotels & Resorts
      • Leisure & Tourism
      • Outdoors, Camping & Hiking
      • Passenger Aviation
      • Travel Industry
      • View All Travel

  • Policy & Public Interest
      • Policy & Public Interest

      • Animal Welfare
      • Corporate Social Responsibility
      • Economic News, Trends & Analysis
      • Education
      • Environmental
      • European Government
      • Labour & Union
      • Natural Disasters
      • Not For Profit
      • Public Safety
      • View All Policy & Public Interest

  • People & Culture
      • People & Culture

      • Aboriginal, First Nations & Native American
      • African American
      • Asian American
      • Children
      • Diversity, Equity & Inclusion
      • Hispanic
      • Lesbian, Gay & Bisexual
      • Men's Interest
      • People with Disabilities
      • Religion
      • Senior Citizens
      • Veterans
      • Women
      • View All People & Culture

  • Explore Our Platform
  • Plan Campaigns
  • Create with AI
  • Distribute Press Releases
  • Report Results
  • Amplify Content
  • All Products
  • General Inquiries
  • Worldwide Offices
  • Hamburger menu
  • PR Newswire: news distribution, targeting and monitoring
  • Send a Release
    • Telephone

    • +91 22-69790010 from 9 AM - 5:30 PM IST

    • Contact
    • Contact

      +91 22-69790010
      from 9 AM - 5:30 PM IST

  • When typing in this field, a list of search results will appear and be automatically updated as you type.

  • Request More Information
  • Journalists
  • News in Focus
    • Browse All News
    • Multimedia Gallery
  • Business & Money
    • Auto & Transportation
    • Business Technology
    • Entertain­ment & Media
    • Financial Services & Investing
    • General Business
  • Science & Tech
    • Consumer Technology
    • Energy & Natural Resources
    • Environ­ment
    • Heavy Industry & Manufacturing
    • Telecomm­unications
  • Lifestyle & Health
    • Consumer Products & Retail
    • Entertain­ment & Media
    • Health
    • Sports
    • Travel
  • Policy & Public Interest
    • Policy & Public Interest
  • People & Culture
    • People & Culture
  • Request More Information
  • Journalists
  • Explore Our Platform
  • Plan Campaigns
  • Create with AI
  • Distribute Press Releases
  • Report Results
  • Amplify Content
  • All Products
  • Request More Information
  • Journalists
  • General Inquiries
  • Worldwide Offices
  • Request More Information
  • Journalists

'Made in India - The story of Desh Bandhu Gupta, Lupin and Indian Pharma' Book Launched in Mumbai
  • Italia - Italiano
  • BRAZIL - Portuguese
  • MEXICO - Spanish
  • APAC - Traditional Chinese
  • Korea - 한국어
  • USA - Deutsch
  • Japan - Japanese
  • USA - Français
  • USA - English
  • USA - español

Lupin Logo (PRNewsfoto/Lupin Limited)

News provided by

Lupin Limited

09 Feb, 2026, 16:07 IST

Share this article

Share toX

Share this article

Share toX

MUMBAI, India, Feb. 9, 2026 /PRNewswire/ -- Made in India, written by Sundeep Khanna and Manish Sabharwal, traces three remarkable journeys: the rise of India's pharma industry, the birth and evolution of Lupin (BSE: 500257) (NSE: LUPIN) (REUTERS: LUPIN.BO) (BLOOMBERG: LPCIN) and the extraordinary life of its founder, Desh Bandhu Gupta. Together, the three journeys illuminate how a country once completely dependent on imported medicines became the world's pharmacy. The book shares how an individual's life, shaped early by adversity, growing up without privilege or patronage, unpredictably nurtured hunger and drive, to navigate an unforgiving state, blend national health priorities and global standards, to build a multibillion-dollar enterprise whose medicines reach patients in over 120 countries.

Continue Reading
(L to R) - Dilip Shanghvi, Sun Pharma; Dr. Yusuf Hamied, Cipla; G.V. Prasad, Dr. Reddy’s; Prof. M. M. Sharma, Ex-(UDCT) ICT; Vinita Gupta, Lupin; Moderator, Manish Sabharwal.
(L to R) - Dilip Shanghvi, Sun Pharma; Dr. Yusuf Hamied, Cipla; G.V. Prasad, Dr. Reddy’s; Prof. M. M. Sharma, Ex-(UDCT) ICT; Vinita Gupta, Lupin; Moderator, Manish Sabharwal.
(L to R) - Author Sundeep Khanna; Chiki Sarkar, Juggernaut Books;  Manju D Gupta, Lupin;  Dilip Shanghvi, Sun Pharma; Vinita Gupta, Lupin; Dr. Yusuf Hamied, Cipla; Prof. M. M. Sharma, Ex-(UDCT) ICT; G.V. Prasad, Dr. Reddy’s;  Nilesh Gupta, Lupin; Author Manish Sabharwal.
(L to R) - Author Sundeep Khanna; Chiki Sarkar, Juggernaut Books; Manju D Gupta, Lupin; Dilip Shanghvi, Sun Pharma; Vinita Gupta, Lupin; Dr. Yusuf Hamied, Cipla; Prof. M. M. Sharma, Ex-(UDCT) ICT; G.V. Prasad, Dr. Reddy’s; Nilesh Gupta, Lupin; Author Manish Sabharwal.

Made in India shows the distance travelled by a village boy from Rajasthan, who went on to become a teacher, professor and pharmaceutical employee, before founding a company worth $10 billion. It is the story of how an unlikely entrepreneur, given his role models, fought the system and left teaching and pharma jobs, going on to build a successful company, giving wings to a world-class industry and became a business icon for a nation.

Written with candor by TeamLease Services co-founder Manish Sabharwal and journalist Sundeep Khanna, the book confronts failures, financial crises, and the personal toll of leadership, alongside achievement and success, in the building of one of the world's biggest generics firms. This is a riveting portrait of entrepreneurship without mythmaking – of how institutions are built slowly, tested severely and rebuilt with resolve. Made in India weaves vivid anecdotes tracing Desh Bandhu Gupta's transformation from a humble professor to a pharma titan, finding his true calling in tending to the unmet needs of people. It issues a powerful call to future leaders, showcasing his journey of visionary entrepreneurship: rising from setbacks with raw grit and unshakeable conviction. 

Made in India also spotlights Desh Bandhu Gupta's wife Manju Gupta's pivotal role amid the trials and triumphs of building Lupin. Together, the couple also built community service and rural support programs, even as Lupin and India became a reliable global supplier of pharmaceuticals.

India has today become the world's pharmacy: Nearly half of the 400 billion pills Americans consume every year are made in India, as are 60 per cent of the world's vaccines. Of the 700 US Food and Drug Administration-approved factories that sell medicines in the US, a third are located in India. The co-creators of Indian pharma – Dr. Yusuf Hamied (Cipla), Anji Reddy (Dr. Reddy's), Parvinder Singh (Ranbaxy), Dilip Shanghvi (Sun), Ramanbhai Patel (Zydus-Cadila), Habil Khorakiwala (Wockhardt) and DBG (Lupin) – matter more to India than their companies' revenues, exports or profits because they saw something no one else did. Together, they raised India's soft and hard power, demolished the myth that multinationals possess unfair advantages over Indian companies, and ended pessimism about India's ability to export goods, making pharma India's biggest manufacturing success. Together, they showed the world that a developing nation can dominate a complex industry when brilliant entrepreneurs meet smart policy. Together, they made India 'Pharmacy to the world'.

Made in India came alive during the launch as the authors, and the publisher shared their journeys, followed by a rich and engaging panel discussion on 'Past and Future of Indian Pharma' with pharma leaders Dilip Shanghvi, Sun Pharma, Dr. Yusuf Hamied, Cipla, G.V. Prasad, Dr. Reddy's, Vinita Gupta, Lupin, and Prof. M. M. Sharma, Ex-(UDCT) ICT. The panel discussed insights on leadership, nation-building, and the Indian pharma industry's crucial role in making healthcare affordable and accessible globally. 

Praise for the book:

Dilip Sanghvi of Sun Pharma said, "DBG was a visionary whose heart beat for India and for Indian patients. His relentless focus on excellence defined his personality. He was a remarkable role model for all of us and one of the true architects who helped shape India's journey to becoming the pharmacy to the world".

Yusuf Hamied of Cipla said, "DBG built Lupin from extremely modest beginnings, guided by determination and a deep commitment to serving patients. DBG's life story is not only inspiring, but also a reminder of how one individuals purpose can make healthcare accessible and affordable across the world".

Made in India is a book for everyone thinking about India's place in the world, seeking role models of a world leading industry from India, entrepreneurs and business people looking for inspiration about building a valuable company, and finally, India's young and their parents, aiming to build ambition, exploration and determination. 

About Lupin

Lupin Limited is a global pharmaceutical leader headquartered in Mumbai, India, with products distributed in over 120 markets. Lupin specializes in pharmaceutical products, including branded and generic formulations, complex generics, biotechnology products, and active pharmaceutical ingredients. Trusted by healthcare professionals and consumers globally, the company enjoys a strong position in India and the U.S. across multiple therapy areas, including respiratory, cardiovascular, anti-diabetic, anti-infective, gastrointestinal, central nervous system, and women's health. Lupin has 15 state-of-the-art manufacturing sites and 7 research centers globally, along with a dedicated workforce of over 24,000 professionals. Lupin is committed to improving patient health outcomes through its subsidiaries - Lupin Diagnostics, Lupin Digital Health, and Lupin Manufacturing Solutions. Lupin Human Welfare and Research Foundation has impacted more than 2.02 million beneficiaries across 5400 villages in 26 districts, spread across eight states in India.

To know more, visit www.lupin.com or follow us on LinkedIn https://www.linkedin.com/company/lupin 

Photo: https://mma.prnewswire.com/media/2889765/Panel_Discussion_Lupin.jpg
Photo: https://mma.prnewswire.com/media/2889762/Book_Launch_Lupin.jpg
Logo: https://mma.prnewswire.com/media/2461104/Lupin_Logo.jpg

Modal title

Also from this source

Lupin Completes Acquisition of VISUfarma

Lupin Completes Acquisition of VISUfarma

Global pharma major Lupin Limited (Lupin) (BSE: 500257) (NSE: LUPIN) (REUTERS: LUPIN.BO) (BLOOMBERG: LPCIN) announced the completion of its...

Lupin Ranks No. 1 Globally in Pharma; Tops All Sectors in India in S&P ESG Assessment 2025

Lupin Ranks No. 1 Globally in Pharma; Tops All Sectors in India in S&P ESG Assessment 2025

Global pharma major Lupin Limited (Lupin) (BSE: 500257) (NSE: LUPIN) (REUTERS: LUPIN.BO) (BLOOMBERG: LPCIN) today announced its recognition among the ...

More Releases From This Source

Explore

Retail

Retail

Health Care & Hospitals

Health Care & Hospitals

Medical Pharmaceuticals

Medical Pharmaceuticals

Pharmaceuticals

Pharmaceuticals

News Releases in Similar Topics

Contact PR Newswire

  • +91 22-69790010

Global Sites

  • APAC
  • APAC - Traditional Chinese
  • Asia
  • Brazil
  • Canada
  • Czech
  • Denmark
  • Finland
  • France
  • Germany

 

  • India
  • Indonesia
  • Israel
  • Italy
  • Mexico
  • Middle East
  • Middle East - Arabic
  • Netherlands
  • Norway
  • Poland

 

  • Portugal
  • Russia
  • Slovakia
  • Spain
  • Sweden
  • United Kingdom
  • United States

Do not sell or share my personal information:

  • Submit via [email protected] 
  • Call Privacy toll-free: 877-297-8921
Global Sites
  • Asia
  • Brazil
  • Canada
  • Czech
  • Denmark
  • Finland
  • France
  • Germany
  • India
  • Israel
  • Italy
  • Mexico
  • Middle East
  • Netherlands
  • Norway
  • Poland
  • Portugal
  • Russia
  • Slovakia
  • Spain
  • Sweden
  • United Kingdom
  • United States
+91 (0) 22 6169 6000
from 9 AM - 5:30 PM IST
  • Terms of Use
  • Privacy Policy
  • GDPR
  • Information Security Policy
  • Site Map
  • Cookie Settings
Copyright © 2026 Cision US Inc.